<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Tranexamic Acid - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Tranexamic Acid</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../index.html">Home</a>
        <a class="btn small" href="../medications.html">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Cardiac / Vascular</div>
      <h1>Tranexamic Acid</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Tranexamic Acid 100mg/mL Injection 10mL</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Trauma-associated hemorrhage (within 3 hours of injury)</strong>
            <ul>
              <li>Loading dose: 1 g IV over 10 minutes</li>
              <li>Followed by: 1 g IV infusion over 8 hours</li>
              <li>Must be given within 3 hours of injury; benefit decreases after 3 hours and may be harmful if &gt;3 hours post-injury</li>
            </ul>
          </li>
          <li><strong>Heavy menstrual bleeding (acute management)</strong>
            <ul>
              <li>1 g IV or 1.3 g PO TID for up to 5 days during menstruation (if oral formulation available)</li>
              <li>Onboard IV formulation can be used if IV access in place; otherwise consider evacuation for severe cases</li>
            </ul>
          </li>
          <li><strong>Other acute bleeding (off-label; per medical direction)</strong>
            <ul>
              <li>1 g IV over 10 minutes; may repeat based on clinical response and medical guidance</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Trauma-associated hemorrhage with significant bleeding or risk of significant bleeding (early treatment critical)</li>
          <li>Life-threatening hemorrhage when evacuation is delayed or unavailable (case-by-case medical direction)</li>
          <li>Heavy menstrual bleeding (when clinically significant and other measures insufficient)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Active thromboembolic disease (DVT, PE, acute MI, stroke) or high thrombotic risk</li>
          <li>History of seizures (tranexamic acid can lower seizure threshold, especially at high doses)</li>
          <li>Subarachnoid hemorrhage (increased risk of cerebral ischemia/infarction)</li>
          <li>Do NOT use &gt;3 hours post-trauma—may increase mortality; timing is critical</li>
          <li>Renal impairment: dose reduction required (CrCl &lt;30 mL/min: reduce dose or extend dosing interval)</li>
          <li>Use caution in patients with history of VTE, atrial fibrillation, or cardiovascular disease</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Nausea, vomiting, diarrhea</li>
          <li>Dizziness, headache</li>
          <li>Hypotension (if infused too rapidly)</li>
          <li>Thromboembolic events (DVT, PE, stroke, MI—uncommon but serious)</li>
          <li>Seizures (dose-related; rare at recommended doses)</li>
          <li>Visual disturbances (rare)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>IV injection/infusion: 100 mg/mL concentration (10 mL vial = 1 g total)</li>
          <li>Loading dose: dilute 1 g (10 mL) in 100 mL normal saline or D5W; infuse over 10 minutes</li>
          <li>Maintenance infusion: dilute 1 g (10 mL) in 250–500 mL normal saline or D5W; infuse over 8 hours</li>
          <li>Do NOT administer as rapid IV bolus—risk of hypotension</li>
          <li>Compatible with most IV solutions; can be given via same line as crystalloids but avoid mixing with blood products in same syringe/bag</li>
          <li>Timing is critical in trauma: start as soon as possible within 3 hours of injury</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Hemodynamic status: BP, HR, signs of ongoing bleeding</li>
          <li>Clinical response: reduction in bleeding, stabilization of vital signs</li>
          <li>Thromboembolic signs: chest pain, shortness of breath, leg swelling/pain, neurological changes</li>
          <li>Seizure activity (especially in high-risk patients or if higher doses considered)</li>
          <li>Renal function if prolonged use or pre-existing renal impairment</li>
          <li>Volume status and need for concurrent resuscitation (crystalloids, blood products if available)</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Trauma hemorrhage: administer within 3 hours of injury—document exact time of injury and time of administration</li>
          <li>Do NOT delay evacuation to give tranexamic acid; give en route if within 3-hour window</li>
          <li>Tranexamic acid is an adjunct to hemorrhage control—continue direct pressure, tourniquets, wound packing, and hemostatic dressings as indicated</li>
          <li>Ensure IV access secured before starting infusion; prepare maintenance infusion to follow loading dose without delay</li>
          <li>If patient has history of clotting disorders or recent VTE, discuss risk/benefit with medical direction before administration</li>
          <li>Monitor closely for hypotension during infusion; slow rate if BP drops</li>
          <li>Document clear indication, time of injury, time of administration, and clinical response</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (tranexamic acid injection): <a href="https://pdf.hres.ca/dpd_pm/00067779.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00067779.PDF</a></li>
          <li>CRASH-2 Trial (tranexamic acid in trauma): <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60835-5/fulltext" target="_blank" rel="noopener">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60835-5/fulltext</a></li>
          <li>Medscape reference (tranexamic acid): <a href="https://reference.medscape.com/drug/cyklokapron-lysteda-tranexamic-acid-342272" target="_blank" rel="noopener">https://reference.medscape.com/drug/cyklokapron-lysteda-tranexamic-acid-342272</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
